Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 11/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486026 | 1.00 | HCAR2 (0.50) | HCAR2MAPK10AURKARIPK1HSD17B10 | |
| SCHEMBL4477061 | 0.89 | HCAR2 (0.47) | HCAR2MAPK10AURKARIPK1HSD17B10 | |
| SCHEMBL13631571 | 0.89 | HCAR2 (0.47) | HCAR2MAPK10AURKARIPK1HSD17B10 | |
| SCHEMBL4491886 | 0.89 | HCAR2 (0.47) | HCAR2MAPK10AURKARIPK1HSD17B10 | |
| SCHEMBL4478915 | 0.88 | HCAR2 (0.41) | HCAR2MAPK10AURKARIPK1HSD17B10 | |
| SCHEMBL13673226 | 0.88 | HCAR2 (0.41) | HCAR2MAPK10AURKARIPK1HSD17B10 | |
| SCHEMBL4500079 | 0.88 | HCAR2 (0.41) | HCAR2MAPK10AURKARIPK1HSD17B10 | |
| SCHEMBL13631585 | 0.86 | HCAR2 (0.49) | HCAR2MAPK10AURKARIPK1HSD17B10 | |
| SCHEMBL4486200 | 0.86 | HCAR2 (0.49) | HCAR2MAPK10AURKARIPK1HSD17B10 | |
| SCHEMBL4476883 | 0.85 | HCAR2 (0.61) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612106-B2 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090258892-A1 | FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20060205955-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. (US) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258892-A1 | FUSED PYRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF | ACE, ACE2, AGTR2 | HCAR2 300/4885MAPK10 4448/4885AURKA 3931/4885 |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | HCAR2 300/4885MAPK10 4448/4885AURKA 3931/4885 |
| US-20060205955-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | HCAR2 300/4885MAPK10 4448/4885AURKA 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.